ELI LILLY & Co (LLY)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2025-12-30

Key Insights

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co, sold 3,593 shares of common stock on December 29, 2025 at a weighted average price of $1,085.035 per share.
This sale represents a small portion (less than 0.004%) of Lilly Endowment's total shareholding of 92,190,516 shares in Eli Lilly & Co.
The transaction appears to be a routine portfolio rebalancing activity and does not necessarily indicate a significant change in Lilly Endowment's long-term view on Eli Lilly & Co.

Insider Trading Filed: 2025-12-29

Key Insights

Lilly Endowment Inc., a significant 10% owner of Eli Lilly & Co (LLY), sold 240 shares of common stock on December 23, 2025 at a weighted average price of $1,085.038.
The transaction represents a small fraction of Lilly Endowment's total stake of over 92 million shares, suggesting this was likely a routine portfolio adjustment rather than a major shift in their investment position.
Insider selling should be monitored, but this sale does not appear to signal any major concerns or changes in Lilly Endowment's long-term outlook on the company.

Insider Trading Filed: 2025-12-29

Key Insights

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co (LLY), has sold 2,629 shares of common stock on December 24, 2025 at a weighted average price of $1,085.173.
The sale of shares by a major institutional investor like Lilly Endowment Inc. could signal a change in their investment outlook or portfolio rebalancing.
Investors should monitor any further selling activity by Lilly Endowment Inc. and assess its potential impact on the stock price and overall investor sentiment towards Eli Lilly & Co.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.